Navigation Links
1-year results of ADAPT-DES trial published in The Lancet
Date:7/26/2013

NEW YORK, NY -- Patients who receive a drug-eluting stent (DES) and demonstrate high platelet reactivity on clopidogrel are more likely to have blood clots form on the stent and to suffer a heart attack; however, these patients are less likely to develop bleeding complications. One-year results of the ADAPT-DES trial will be published online July 26, 2013, in The Lancet. The findings were first presented at last year's Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium.

ADAPT-DES is the largest study ever to explore the overall treatment implications of platelet reactivity on patient outcomes after successful coronary drug-eluting stent implantation. Researchers investigated the relationship between platelet reactivity during dual therapy with aspirin and clopidogrel and clinical outcomes such as stent thrombosis, major bleeding, and other adverse events.

The study enrolled 8,583 patients at 11 sites in the US and Germany who underwent a percutaneous coronary intervention (PCI) with at least one drug-eluting stent between January 7, 2008, and September 16, 2010. Researchers assessed platelet reactivity with the VerifyNow Aspirin, P2Y12, and IIb/IIIa tests. Patients were followed for one year to determine the relationship between platelet reactivity and subsequent events. At one year, stent thrombosis had occurred in 70 patients (0.8 percent), heart attack in 269 (3.1 percent), major bleeding in 531 (6.2 percent), and death in 161 (1.9 percent).

Platelet reactivity units (PRU), an index of platelet inhibition to clopidogrel, were measured by the VerifyNow P2Y12 test. High platelet reactivity, defined as a PRU of greater than 208, was present in 42.7 percent of patients. At one year, researchers found that high platelet reactivity was significantly associated with stent thrombosis (1.3 percent vs. 0.5 percent) and heart attack (3.9 percent vs. 2.7 percent), but was also found to be protective against major bleeding (5.6 percent vs. 6.7 percent). High platelet reactivity was also associated with one-year mortality (2.4 percent vs. 1.5 percent). However, because high platelet reactivity is also associated with other patient risk factors and baseline characteristics, multivariable modeling was also performed; it showed no independent association between high platelet reactivity and mortality.

"Results from the ADAPT-DES registry definitely demonstrate that high platelet reactivity after implantation of drug-eluting stents is an independent predictor of one-year stent thrombosis and heart attack, but it is also protective against major bleeding, both of which impact mortality," said lead investigator Gregg W. Stone, MD. Dr Stone is professor of medicine at Columbia University College of Physicians and Surgeons and Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center. Dr. Stone is also co-director of the Medical Research and Education Division at the Cardiovascular Research Foundation (CRF).

"Because of the counteracting effects of ischemia and bleeding, platelet reactivity was not an independent predictor of one-year mortality. Therefore, overcoming high platelet reactivity with more potent antiplatelet agents is unlikely to improve survival unless the beneficial effect of reducing stent thrombosis and heart attack can be separated from the likely increase in bleeding that results from greater platelet inhibition," said Dr. Stone.

Dr. Stone added: "Platelet reactivity on aspirin was unrelated to stent thrombosis, heart attack, or death, but may be related to bleeding. This raises questions as to the utility of aspirin in patients treated with drug-eluting stents."


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of landmark 11-year study on weight losss effect on heart disease risks published today
2. SchizLife.com Celebrates 1-Year Anniversary, Debunks Harmful Schizophrenia Myths
3. 1-year results of ADAPT-DES presented at TCT 2012
4. SEARCH study shows 1-year drop in HIV virus levels in rural Ugandan parish after campaign
5. Presentation of 1-year IVAN and 2-year CATT study results
6. Carb Back-Loading Diet Review: Results and Sample Meal Plan Exposed by Daily Gossip Magazine
7. New Results from Orriant’s Corporate Wellness Programs are Demonstrating the Benefits of Tobacco Cessation
8. Beverly Hills Hair Restoration Surgeon Revises Unnatural Hair Transplant Results, Releases High-Definition Video of FUE Procedure
9. Weill Cornell presents updated results from Phase 3 trial of IVIG for Alzheimers disease
10. Monroe, CT Dental Implants Are Now Computer Guided from Dr. Richard Amato for Precise Results
11. Baseball players enjoy successful long-term results after elbow surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2019)... N.Y. (PRWEB) , ... October 10, 2019 , ... ... Sports Nutrition) Annual Conference, Nutrition 21 was excited to hear the significant results ... the significant blood flow impact of Nitrosigine®. The clinical study poster entitled “The ...
(Date:10/8/2019)... ... ... SoCal Adolescent Wellness announces the opening of a second location in Lake ... better serve the families in Orange County," said Becca Moody, CEO of SoCal Adolescent ... this pre-intervention program has on the lives of the adolescents and families we work ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... services for the Department of Veterans Affairs Community Care Referrals and Authorizations program. ... of the VA’s Health Share Referral Manager (HSRM), an enterprise-wide system used by ...
(Date:10/8/2019)... ... 2019 , ... PotentiaMetrics, an Austin, TX based healthcare data ... Officer. Dr. Henderson will be responsible for the development and management of the ... Chair of both the Informatics Governance and the Inpatient Clinical Informatics Committees at ...
(Date:10/8/2019)... ... October 08, 2019 , ... METAvivor Research and Support Inc., ... the launch of its Stage IV Stampede campaign. The campaign will commence with two ... that will include an advocacy boot camp, a march, a Die-In (hosted by partner ...
Breaking Medicine News(10 mins):
(Date:10/10/2019)... ... October 10, 2019 , ... Ovation Fertility is once again ... reproductive medicine, with six abstracts accepted for poster presentations at the ASRM 2019 ... 12-16, 2019, in Philadelphia. , “Ovation will have a prominent presence in the ...
(Date:10/9/2019)... AVERILL PARK, N.Y. (PRWEB) , ... October 09, ... ... conference will present the nation’s only complete teaching of Yoga Science and AMI ... and Science of Yoga, this comprehensive training, held October 22-26, 2019 at ...
(Date:10/8/2019)... Charleston, SC (PRWEB) , ... October 08, 2019 ... ... Sedation Dentistry of Charleston. Dr. Robert Carimi and his caring team are thrilled ... who suffer from dental anxiety in Charleston, SC. The mission of ...
Breaking Medicine Technology: